VANCOUVER, British Columbia, May 17, 2013 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced that the nominees listed in the management proxy circular for the 2013 Annual and Special Meeting of Shareholders were elected as directors of Tekmira at the annual meeting held on May 14, 2013 in Vancouver. Detailed results of the vote for the election of directors are set out below:
| Nominee | Votes For | % For | Votes Withheld | % Withheld |
| Michael Abrams | 1,944,876 | 99.25% | 14,740 | 0.75% |
| Kenneth Galbraith | 1,945,046 | 99.26% | 14,570 | 0.74% |
| Don Jewell | 1,945,116 | 99.26% | 14,500 | 0.74% |
| Frank Karbe | 1,942,816 | 99.14% | 16,800 | 0.86% |
| Daniel Kisner | 1,943,276 | 99.17% | 16,340 | 0.83% |
| Mark J. Murray | 1,942,146 | 99.11% | 17,470 | 0.89% |
About Tekmira
Tekmira Pharmaceuticals Corporation is a biopharmaceutical company focused on advancing novel RNAi therapeutics and providing its leading lipid nanoparticle delivery technology to pharmaceutical partners. Tekmira has been working in the field of nucleic acid delivery for over a decade and has broad intellectual property covering LNPs. Further information about Tekmira can be found at www.tekmirapharm.com. Tekmira is based in Vancouver, B.C.